BACKGROUND: The objective of this study was to identify relevant quality of life (QOL) issues in patients with head and neck cancer receiving multimodal and/or targeted therapies. METHODS: The literature was searched for QOL issues reported after multimodal and/or targeted therapies resulting in a list of potentially relevant issues. These were discussed within a multiprofessional expert group, revised, and subsequently rated for relevance by patients and health care providers. RESULTS: Twenty-seven issues were extracted that are not covered by the current version of the European Organization for Research and Treatment of Cancer (EORTC) questionnaires. Interviews (96 health care providers from 13 countries, 137 patients from 8 countries) revealed that 26 of these issues were relevant for patients with head and neck cancer. CONCLUSIONS: Studies investigating targeted and/or multimodal therapy should consider that some QOL issues specific to these treatments are not covered by the current version of the EORTC instruments. Consequently, the EORTC head and neck cancer module is currently in revision.
BACKGROUND: The objective of this study was to identify relevant quality of life (QOL) issues in patients with head and neck cancer receiving multimodal and/or targeted therapies. METHODS: The literature was searched for QOL issues reported after multimodal and/or targeted therapies resulting in a list of potentially relevant issues. These were discussed within a multiprofessional expert group, revised, and subsequently rated for relevance by patients and health care providers. RESULTS: Twenty-seven issues were extracted that are not covered by the current version of the European Organization for Research and Treatment of Cancer (EORTC) questionnaires. Interviews (96 health care providers from 13 countries, 137 patients from 8 countries) revealed that 26 of these issues were relevant for patients with head and neck cancer. CONCLUSIONS: Studies investigating targeted and/or multimodal therapy should consider that some QOL issues specific to these treatments are not covered by the current version of the EORTC instruments. Consequently, the EORTC head and neck cancer module is currently in revision.
Authors: Talya Salz; Jamie S Ostroff; Chandylen L Nightingale; Thomas M Atkinson; Eleanor C Davidson; Sankeerth R Jinna; Anuja Kriplani; Glenn J Lesser; Kathleen A Lynch; Deborah K Mayer; Kevin C Oeffinger; Sujata Patil; Andrew L Salner; Kathryn E Weaver Journal: Contemp Clin Trials Date: 2021-05-21 Impact factor: 2.261
Authors: Arnold Degboe; Sarah L Knight; Katarina Halling; Andrew Trigg; Tamara Al-Zubeidi; Natalie Aldhouse; Helen Kitchen; Lori Wirth; Simon N Rogers Journal: J Patient Rep Outcomes Date: 2018-08-01
Authors: Prianka Singh; Bryan Bennett; Tom Bailey; Gavin Taylor-Stokes; Ivana Rajkovic; Marta Contente; Sharon Curtis; Chris Curtis Journal: BMC Cancer Date: 2021-07-24 Impact factor: 4.430